Closing arguments in the patent trial between Xoma Corp. andCentocor Inc., scheduled to begin on Monday, have beenrescheduled to begin today. The trial in U.S. District Court inSan Francisco was delayed when a major fire in the Oakland-Berkeley Hills prevented some jurors from reaching thecourthouse. Xoma and Centocor have competing antibodyproducts to treat gram-negative sepsis. Xoma stock(NASDAQ:XOMA) rose $1.25 on Monday to close at $16.50.Centocor (NASDAQ:CNTO) dropped $2, closing at $51.50.
(c) 1997 American Health Consultants. All rights reserved.